Founded
Address
Clarus Ventures LLC
One Memorial Drive
Suite 1230
Cambridge, MA 02142
United States
Phone
Website
Recent investment activity
KANDO id: 30972
Company type
Life sciences venture capital firmRelation
Renamed to
Funding rounds
Investment preferences
Investment activity status
Not investing
Selected investments
Displaying 26 - 38 of 38| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Delenex Therapeutics AG | N/A | ||||
|
|
Oxford Immunotec Ltd | Series D | ||||
|
|
FerroKin Biosciences Inc | A clinical stage biotechnology company dedicated to improving the management of patients with iron overload. | N/A | |||
|
|
Flowonix Medical | A medical device company dedicated to helping those who suffer from chronic disorders. | N/A | |||
|
|
Globus Medical Inc | A medical device company, focuses on the design, development, and commercialization of products that promote healing in patients with spine disorders. | Series E | |||
|
|
Heptares Therapeutics Ltd | Series A | ||||
|
|
Link Medicine Inc | Advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases | Series C | |||
|
|
Lycera Corp | Series A | ||||
|
|
Oxford Immunotec Ltd | Series C led the round | ||||
|
NanoString Technologies Inc | A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. | Series C | |||
|
|
NanoString Technologies Inc | A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. | Series D | |||
|
Zogenix Inc | A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. | N/A Initial investment | |||
|
|
Zogenix Inc | A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. | Series B Follow-on investment |